GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intravenous Infusion of GW328267X in Healthy Volunteers
Phase 1
Completed
- Conditions
- Lung Injury, Acute
- Interventions
- Drug: SalineDrug: GW328267X (total dose of 12mcg)Drug: GW328267X (total dose of 40mcg)
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3
- Registration Number
- NCT01640990
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects
Phase 3
Completed
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Meningococcal vaccine GSK134612
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 86
- Registration Number
- NCT01641042
- Locations
- 🇨🇿
GSK Investigational Site, Hradec Kralove, Czechia
Effect of Fluoride in a Dentifrice on Remineralization of Erosive Lesions
Phase 3
Completed
- Conditions
- Enamel Erosion
- Interventions
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 72
- Registration Number
- NCT01641237
- Locations
- 🇺🇸
Indiana University School of Dentistry, Indianapolis, Indiana, United States
Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™
Phase 3
Completed
- Conditions
- Infections, StreptococcalStreptococcus Pneumoniae Vaccines
- Interventions
- Biological: Synflorix (3-Dose)Biological: Synflorix (2-Dose)Biological: Synflorix (Single Dose)Biological: Prevenar 13 (Single Dose)Biological: Prevenar 13 (2-Dose)
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 457
- Registration Number
- NCT01641133
- Locations
- 🇲🇽
GSK Investigational Site, Mexico, Mexico
Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 45
- Registration Number
- NCT01636778
- Locations
- 🇯🇵
GSK Investigational Site, Wakayama, Japan
SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28855
- Registration Number
- NCT01636271
Special Drug Use Investigation for ROTARIX®
Completed
- Conditions
- Infections, Rotavirus
- Interventions
- Biological: Oral Rotarix®Other: Data collection
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10982
- Registration Number
- NCT01636739
WEUKBRE5554: IMI PROTECT(Work Package 2): Beta2 Agonists and Acute Myocardial Infarction
Completed
- Conditions
- Asthma
- Interventions
- Drug: Inhaled LABA use
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01636726
A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: GSK573719/VI 62.5/25Drug: GSK573719/VI 125/25Drug: Placebo
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 581
- Registration Number
- NCT01636713
- Locations
- 🇹🇭
GSK Investigational Site, Nan, Thailand
Drug Use Investigation for ROTARIX®
Completed
- Conditions
- Infections, Rotavirus
- Interventions
- Biological: Oral Rotarix®Other: Data collection
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2015-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1607
- Registration Number
- NCT01636193
© Copyright 2025. All Rights Reserved by MedPath